HAVEN is a leadership development firm that partners with high-growth biotech companies to provide leadership development. HAVEN ignites exceptional performance and cultivates capabilities in leaders and teams through Leadership Development training, Executive Coaching, and Team Coaching. HAVEN’s innovative training programs are especially designed for rapidly scaling companies that want to help their managers develop leadership skills required to engage people and teams to achieve their best. HAVEN works with clients to design custom programs to address their specific goals and align with the organizational culture. HAVEN executive coaches work with leaders 1:1 to explore their leadership opportunities, to deepen understanding and create lasting behavior change. HAVEN team coaching helps leadership teams diagnose their challenges and implement solutions to perform at their best.

Our mission is to enable and finance the development of life-saving genetic medicines for rare and ultra-rare patient populations previously deemed too rare to treat. To realize this, our unique ecosystem facilitates collaboration between world-renowned researchers and clinicians, policy experts and our generous donors. Together, we are fundamentally changing the rare and ultra-rare disease experience and burden for millions of people around the world with our discoveries and methods—while bringing hope to patients waiting for a cure.

Research Activities: Advanced modalities drug development for rare and ultra-rare neuromuscular and neurodegenerative diseases.

Intensity Therapeutics is a clinical-stage biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class cancer drugs that attenuate tumors with minimal side effects, while igniting the patient’s immune system to fight the cancer. Our lead product candidate, INT230-6, has been tested in ~200 patients in human clinical studies to treat refractory solid cancers.

Background and Key Achievements

We have late-stage pipeline programs in metastatic and presurgical settings with multiple near-term inflexion points. We have a robust IP portfolio, a platform validated through multiple Industry, government and university hospital partnerships, positive data that led to partnerships with Merck, Bristol Myers Squibb, and the National Institute of Health.  Recently we completed an oversubscribed, top-of-range initial public offering on the NASDAQ exchange, raising ~$22.5 million. The ticker is INTS.

Curie.Bio is a new model for venture capital in biotech focused on helping founders launch serious biotech therapeutics companies. Founded by Alexis Borisy, Christoph Lengauer, and Zach Weinberg, Curie.Bio is a unique combination of two businesses: they act as both your drug discovery co-pilot & seed investor. They have some of the world’s best drug hunters, drug makers, experts, and vendors supporting founders to increase their chances of developing successful medicines. They help founders avoid mistakes and ensure they have the right data, plan, and story to retain ownership and control over their own company. By doing this, Curie.Bio is enabling more founders with phenomenal ideas to have the support they need to start their own companies. Check out our recent press coverage from STAT, Fast Company, and BIOS.

Bank of America Private Bank offers innovative and customized financial solutions to help meet unique lifestyle, family, business and philanthropic goals for wealthy individuals, families and institutions with complex wealth management needs. A coordinated team backed by more than 200 years of experience and the resources of one of the world’s largest financial institutions works with each client to understand and address their needs. We apply deep wealth management expertise and financial acumen to deliver across a comprehensive range of capabilities, including wealth structuring, investment management, customized credit and banking, legacy and philanthropy, and family office services.

To learn more, please visit: bankofamerica.com/PrivateBank

Vincent Thompson is a Senior Vice President at Bank of America Private Bank. His broad experience spans senior business development roles in the hedge fund and alternative investments business. Leading a team of dedicated specialists, he addresses the financial needs of senior-level corporate executives, business owners, real estate investors, hedge fund and private equity professionals, and generations of wealthy families. Prior to joining The Private Bank, Vincent was Director of Marketing at JPMorgan Incubator Strategies, a venture capital fund focused on seeding hedge funds, a Senior Relationship Manager for Brevan Howard, a large global macro hedge fund, and a Managing Director at Crito Capital, a private placement firm. Vincent holds a BA from the University of Vermont and an MBA in finance from Columbia Business School, where he was a Robert Toigo Fellow.  He also is a CFA® charterholder.

Saghmos Therapeutics is a privately held pharmaceutical company whose mission is to develop innovative therapies for life-threatening cardiovascular and renal diseases with unmet medical needs. Saghmos’ product, ST-62516 (trimetazidine), is poised to enter a Phase 3 study to reduce the risk of Major Adverse Cardiac and Kidney Events (MACKE) after percutaneous coronary intervention (PCI) procedures in patients with unstable angina.

Cardiac and kidney complications after PCI represent an area of significant unmet medical need. There are no approved pharmacological agents to prevent or treat MACKE. Trimetazidine has been approved outside the US for several decades for the treatment of stable angina and ischemic heart failure. In addition, many studies show it reduces kidney injury in patients undergoing PCI. With one million PCI procedures annually in the US, there is a multi-billion dollar opportunity for ST-62516.

Saghmos is seeking funding for the Phase 3 MACKE study, as well as partnering opportunities for ST-62516.

KBE Building Corporation is a full-service commercial construction company founded in Connecticut with its home office in Farmington. KBE is strategically positioned to serve the Eastern, Mid-Atlantic, and Western U.S. through its regional offices in Connecticut, Arizona, and Maryland.

KBE is one of the KBE Companies, which includes KBE-NY, serving clients in metropolitan New York, and New Valley Construction, which works with select clients throughout the US.

With its 200+ preconstruction and construction staff, KBE provides preconstruction, construction management, design-build, and general contracting services to clients  in the senior living, educational, retail, health care, federal, corporate, hospitality & entertainment, and institutional markets.

KBE has the expertise to serve the biotech and life sciences industries through its work for higher education and other research-based institutions where it has created the physical environments that support research and development.

In 2022, KBE launched the KBE Foundation (kbefoundation.org) to formalize the firm’s long tradition of community support. www.kbefoundation.org

OmniCyte is a preclinical stage, immunology based, biotechnology company located in Branford Connecticut. The company was founded with a focus on developing targeted treatments to address significant unmet medical needs. Our therapeutics are developed from our proprietary Targeted Immune Activation, platform technology. The platform consists of a bi-specific protein complex, with a conserved domain that activates an immune response through the dendritic cell, and a variable targeting domain that can be engineered to target numerous tumor types and pathogens. OmniCyte boasts a strong management team and an even stronger bench of advisors & collaborators.

Hamilton Robotics is a global leader in liquid handling and laboratory automation technology, advancing the laboratory analytical sciences through reliability, performance, and flexibility. For more than 70 years, Hamilton has exceeded expectations. The measure of excellence.

In 2022, Apple Tree Partners formed ATP R&D Labs as an in-house incubator and accelerator to drive the foundational science for ATP portfolio companies and spark the beginnings of future ventures.  ATP R&D Labs state-of-the-art facility in New Haven, Connecticut, offers a full suite of services in compound screening, cellular and molecular assays, data analytics, and preclinical pharmacology.

ATP R&D employs in vivo and in vitro methodologies to discover and evaluate small molecules, working closely with ATP’s team of business and scientific experts, senior leaders at ATP portfolio companies, and scientific founders and partners.